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Introduction {#prp2298-sec-0001}
============

Antibiotics rank among the most widely prescribed medications globally (WHO, [2004](#prp2298-bib-0032){ref-type="ref"}; Shehab et al. [2008](#prp2298-bib-0028){ref-type="ref"}; Adriaenssens et al. [2011](#prp2298-bib-0003){ref-type="ref"}). Widespread antibiotic use predisposes patients to antibiotic‐associated adverse drug reactions (aa‐ADRs), including serious aa‐ADRs (WHO‐UMC, 2000). Antibiotics contributed to 19% of emergency department visits for suspected ADRs in the United States (US) between 2004 and 2006 (Shehab et al. [2008](#prp2298-bib-0028){ref-type="ref"}), 8% of ADRs linked to hospital admissions in Greece in 2005 (Alexopoulou et al. [2008](#prp2298-bib-0004){ref-type="ref"}), 6% in Spain between 2001 and 2006 (Carrasco‐Garrido et al. [2010](#prp2298-bib-0009){ref-type="ref"}), 5% in The Netherlands in 2003 (van der Hooft et al. [2008](#prp2298-bib-0013){ref-type="ref"}), and 11% in India between 2002 and 2009 (Sonal et al. [2011](#prp2298-bib-0029){ref-type="ref"}); and are responsible for a considerable proportion of hospital‐acquired ADRs in the US (10%) (Weiss et al. [2011](#prp2298-bib-0034){ref-type="ref"}) and South Africa (22%) (Mehta et al. [2008](#prp2298-bib-0020){ref-type="ref"}). Allergic reactions constitute 79% of aa‐ADRs at US emergency departments (Shehab et al. [2008](#prp2298-bib-0028){ref-type="ref"}).

Developing countries contributed 76% of the global rise in antibiotic use between 2000 and 2010 (Van Boeckel et al. [2014](#prp2298-bib-0033){ref-type="ref"}), which increases their risk of aa‐ADRs. Cotrimoxazole use is standard‐of‐care for prophylaxis against opportunistic infections among HIV/AIDS patients in resource‐limited settings (WHO, [2006](#prp2298-bib-0001){ref-type="ref"}). Thus, the high burden of HIV/AIDS in sub‐Saharan Africa (SSA) implies increased risk of cotrimoxazole‐linked ADRs (Mouton et al. [2015](#prp2298-bib-0021){ref-type="ref"}). Little is known about the frequency (Kiguba et al. [2015](#prp2298-bib-0014){ref-type="ref"}) and characteristics of aa‐ADRs among inpatients in SSA (Mehta et al. [2008](#prp2298-bib-0020){ref-type="ref"}), particularly in Uganda. Moreover, it is a challenge to ascertain aa‐ADR causality in our hospital setting where a large proportion of inpatients have comorbidities and/or concurrently receive multiple medicines.

Four‐fifths of inpatients at a tertiary care public health facility in Uganda consume at least one antibiotic during hospitalization, whereas two‐fifths use at least one antibiotic during the 4‐weeks preadmission (Kiguba et al. [2016a](#prp2298-bib-0015){ref-type="ref"}). Patients can receive parenteral antibiotics at private clinics in the community prior to their subsequent referral to tertiary care public health facilities.

The reported antibiotic prescribing patterns in our hospital setting excluded antituberculous drugs and focused on commonly used antibacterial agents (Kiguba et al. [2016a](#prp2298-bib-0015){ref-type="ref"}), whose prescription is not restricted to specialists, to identify key areas for antibiotic stewardship. For the benefit of antituberculous drugs pharmacovigilance in Uganda, this paper includes data on the aa‐ADRs of antituberculous drugs. We sought to determine the prevalence at hospital admission and the incidence during hospital stay of aa‐ADRs among Ugandan inpatients: their seriousness, rarity, preventability, causality, and severity.

Materials and Methods {#prp2298-sec-0002}
=====================

Study design and setting {#prp2298-sec-0003}
------------------------

This prospective cohort study (Kiguba et al. [2016a](#prp2298-bib-0015){ref-type="ref"}) was conducted among hospitalized adult patients (≥18 years) at the Mulago National Referral Hospital (1790 beds; more than 140,000 inpatients annually). Briefly, three medical wards were studied: Infectious Diseases and Gastrointestinal Illnesses (IDGI); Haematology, Neurology and Endocrinology (HNE); and Cardiovascular, Pulmonology and Nephrology (CPN); and one Gynecology ward (GYN). IDGI and CPN each admitted 10--15 patients/day and HNE received 5--10 patients/day; therefore 25--40 admissions/day on medical wards. However, GYN had 20--25 admissions/day.

Patients gave written informed consent.

Data collection {#prp2298-sec-0004}
---------------

From October to November 2013, we undertook a pilot study on the four wards to assess practicability and to pretest the study instruments. The main study (reported here) was implemented in December 2013 to April 2014. Four trained ward‐teams, each having a medical doctor, pharmacist and degree‐nurse, were to recruit and follow‐up inpatients using a systematic random sampling procedure: three new admissions daily on long‐stay wards (HNE/CPN) and six on short‐stay wards (IDGI/GYN). Ward‐teams randomly selected the first study patient from the first two (IDGI), three (HNE), and four (CPN/GYN) new admissions; and subsequently aimed at recruiting every second, third, and fourth admission, respectively (Kiguba et al. [2016a](#prp2298-bib-0015){ref-type="ref"}).

Baseline patient assessment captured relevant data on demographics, clinical conditions including aa‐ADRs, and antibiotic medications used. Subsequently, daily assessments were conducted until discharge, transfer, death, or loss to follow‐up. Ward‐teams collected data from 8.00am to 6.00 pm from Monday to Friday and from10.00am to 6.00 pm on weekends and public holidays (Kiguba et al. [2016a](#prp2298-bib-0015){ref-type="ref"}).

Data management {#prp2298-sec-0005}
---------------

The data were double‐entered into a database using Epidata 3.1 software (Odense, Denmark) with check programs to limit out‐of‐range data entry errors. Where data discrepancies occurred, the original case report form was cross‐checked and corrections were made.

Identification of aa‐ADRs {#prp2298-sec-0006}
-------------------------

We defined aa‐ADRs according to the WHO definition (WHO‐UMC, [2011](#prp2298-bib-0002){ref-type="ref"}). Clinical examination was the major approach used to identify aa‐ADRs due to limitations in timely availability of laboratory investigation results (Kiguba et al. [2016b](#prp2298-bib-0016){ref-type="ref"}). To increase the probability to detect aa‐ADRs, patients were screened using an ADR trigger tool (Rozich et al. [2003](#prp2298-bib-0024){ref-type="ref"}). To assess causality, a suspected aa‐ADR was assigned to a Naranjo ADR probability category based on a total score obtained from 10 weighted questions. These questions assessed the temporal association between suspected drug and adverse reaction, alternative cause(s) of the reaction, plasma drug levels (if available), dose--response relationships and previous patient experience with the drug. Suspected aa‐ADRs with Naranjo score of 0 were *doubtful,* 1--4 *possible*, 5--8 *probable*, and ≥9 *definite* (Naranjo et al. [1981](#prp2298-bib-0022){ref-type="ref"}). Thus, coding an adverse event as "aa‐ADR" required at least *possible* grading on the Naranjo scale. Operationally, an *aa‐ADR* was any undesirable medical occurrence that developed after the administration of an antibiotic and for which there was, at least, *possible* causality between the antibiotic and the medical occurrence. Consensus agreement on aa‐ADR causality was reached in a committee headed by the ward‐based study physician and senior clinical pharmacist (RK). This team approach reflected the routine on‐ward approach whereby nurses, medical doctors, and clinical pharmacists brainstorm on patients\' clinical problems before making clinical decisions (Kiguba et al. [2016a](#prp2298-bib-0015){ref-type="ref"}). Community‐acquired aa‐ADRs were defined as ADRs linked to preadmission use of antibiotics. Some community‐acquired aa‐ADRs manifested preadmission, whereas others occurred after hospital admission. Hospital‐acquired aa‐ADRs were those linked to hospital‐initiated antibiotics used during the current hospitalization.

Preventability, severity (grade or intensity), and seriousness (incapacitating or life‐threatening) of aa‐ADRs were also determined by consensus as described above. Preventability was assessed using the modified Schumock and Thornton Preventability Scale (Schumock and Thornton [1992](#prp2298-bib-0027){ref-type="ref"}; Lau et al. [2003](#prp2298-bib-0017){ref-type="ref"}), whereas severity was evaluated using the Division of AIDS Table for Grading the Severity of Adult and Paediatric Adverse Events (Division of AIDS (DAIDS), [2004](#prp2298-bib-0011){ref-type="ref"}) and seriousness using the WHO Uppsala Monitoring Centre (UMC) criteria (WHO‐UMC, 2000). Rarity of an aa‐ADR (occurrence in \<0.1% of medication users) (WHO‐UMC, [2011](#prp2298-bib-0002){ref-type="ref"}), was assessed by RK using the British National Formulary (BNF) (British National Formulary, [2014](#prp2298-bib-0008){ref-type="ref"}) as the principal reference.

Statistical analysis {#prp2298-sec-0007}
--------------------

We determined the prevalence of aa‐ADRs at hospital admission, and the incidence of aa‐ADRs during hospitalization. Numerators for prevalence and incidence were the number of patients who had experienced preadmission aa‐ADRs and new cases of in‐hospital aa‐ADRs, respectively, whereas the denominator was the number of study patients who received antibiotics (both incidence and prevalence) or total number of patients in the cohort (prevalence only).

We also computed the incidence of hospital‐acquired aa‐ADRs per 100 defined daily doses (DDDs) (Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) Index, [2015](#prp2298-bib-0006){ref-type="ref"}; Hamad et al. [2013](#prp2298-bib-0012){ref-type="ref"}) of each implicated antibiotic administered during the current hospitalization.

We assessed aa‐ADRs as community‐acquired or hospital‐acquired; and for causality, preventability, severity, seriousness, and rarity.

All statistical analyses were conducted using Stata 12.0 (StataCorp, [2011](#prp2298-bib-0030){ref-type="ref"}).

Ethical clearance {#prp2298-sec-0008}
-----------------

Ethical approval for the study was obtained from the School of Medicine Research and Ethics Committee, Makerere University College of Health Sciences (REC REF No. 2011--113), the Mulago Hospital Research and Ethics Committee (MREC 253), and the Uganda National Council for Science and Technology (HS 1151).

Results {#prp2298-sec-0009}
=======

Study population {#prp2298-sec-0010}
----------------

Of 762 inpatients included in the study, 70% (534/762: 191 in gynecology, 343 in the medical wards) were female. Median age of inpatients was 30 years \[interquartile range (IQR) of 24--42\] and median length of hospital stay was 4 days (IQR: 3--6). Thirty percent were known HIV‐seropositive \[(232/762): 38% (215/571) being on the medical wards and 9% (17/191) on gynecology\], see Table [1](#prp2298-tbl-0001){ref-type="table-wrap"}.

###### 

Demographic and clinical characteristics of 762 hospitalized patients, Uganda, 2014

  Characteristic                                     Number of patients (*n* = 762)[a](#prp2298-note-0002){ref-type="fn"}          Patients with community‐acquired antibiotic‐associated. ADRs at admission                 Patients who developed new antibiotic‐associated. ADRs while in hospital[b](#prp2298-note-0003){ref-type="fn"}                
  -------------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------
  Age, years \[median, interquartile range (IQR)\]   30 (24--42)                                                                   33 (27--42)                                                                               33 (26--40)                                                                                                                   30 (25--39)
  Number of administered medicines (median, IQR)     7 (5--10)                                                                     10 (8--12)                                                                                11 (7--14)                                                                                                                    9 (7--12)
  Length of hospital stay, days (median, IQR)        4 (3--6)                                                                      4 (3--7)                                                                                  7 (5--9)                                                                                                                      6 (5--9)
  Characteristic                                     Number of patients (*n* = 762), % col[a](#prp2298-note-0002){ref-type="fn"}   Patients with community‐acquired antibiotic‐associated ADRs at admission (% Prevalence)   Patients who developed new antibiotic‐associated ADRs while in hospital (% Incidence)[b](#prp2298-note-0003){ref-type="fn"}   
  Community‐acquired                                 Hospital‐acquired                                                                                                                                                                                                                                                                                     
  Gender                                                                                                                                                                                                                                                                                                                                                   
  Male                                               228 \[30\]                                                                    20 (9)                                                                                    9 (4)                                                                                                                         30 (13)
  Female                                             534 \[70\]                                                                    25 (4)                                                                                    14 (3)                                                                                                                        64 (12)
  Ward‐type                                                                                                                                                                                                                                                                                                                                                
  Medical wards                                      571 \[75\]                                                                    40 (7)                                                                                    22 (4)                                                                                                                        68 (12)
  Infectious diseases & gastrointestinal illnesses   320 \[42\]                                                                    19 (6)                                                                                    5 (2)                                                                                                                         31 (10)
  Hematology, neurology & endocrinology              117 \[15\]                                                                    0 (0)                                                                                     2 (2)                                                                                                                         9 (8)
  Cardiovascular, pulmonology & nephrology           134 \[18\]                                                                    21 (16)                                                                                   19 (14)                                                                                                                       28 (21)
  Gynecology ward                                    191 \[25\]                                                                    5 (3)                                                                                     1 (1)                                                                                                                         26 (14)
  HIV status by ward‐type                                                                                                                                                                                                                                                                                                                                  
  Positive                                           232 \[30\]                                                                    38 (16)                                                                                   18 (8)                                                                                                                        34 (15)
  Medical wards                                      215 \[38\]                                                                    37 (17)                                                                                   18 (8)                                                                                                                        29 (13)
  Gynecology ward                                    17 \[9\]                                                                      1 (6)                                                                                     0 (0)                                                                                                                         5 (29)
  Negative or unknown                                530 \[70\]                                                                    7 (1)                                                                                     9 (2)                                                                                                                         60 (11)
  Medical wards                                      356 \[62\]                                                                    3 (1)                                                                                     8 (2)                                                                                                                         39 (11)
  Gynecology ward                                    174 \[91\]                                                                    4 (2)                                                                                     1 (1)                                                                                                                         21 (12)

Of 762 patients, 300 had received antibiotics preadmission, 603 initiated antibiotics during hospital stay, and 629 received antibiotics either preadmission or during hospital stay; square brackets \[\] represent column percentages; round brackets () represent row percentages.

Four patients experienced incident community‐acquired and hospital‐acquired antibiotic‐associated ADRs during the current hospitalization.

John Wiley & Sons, Ltd

Extent of aa‐ADRs {#prp2298-sec-0011}
-----------------

Overall, 42% (320/762; 95% CI: 38--46%) of patients experienced at least one suspected ADR attributable to any medication class: 46% (148/320; 95% CI: 41--52%) of these patients, or 19% (148/762; 95% CI: 17--22%) of all patients, experienced at least one aa‐ADR, see Table [2](#prp2298-tbl-0002){ref-type="table-wrap"}. Fifty‐eight percent (86/148) of the patients with aa‐ADRs encountered hospital‐acquired aa‐ADRs only, 37% (54/148) had community‐acquired aa‐ADRs only and 5% (8/148) both community‐acquired (incident and prevalent) and hospital‐acquired aa‐ADRs.

###### 

Extent of antibiotic‐associated suspected ADRs at patient‐level among 762 inpatients, Uganda, 2014

  Characteristic at patient‐level                                                                                                             Number of suspected ADRs, *n*                                   
  ------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- ----------------- ---------------
  Suspected ADRs attributed to any medication class                                                                                           136                                           184               320
  Antibiotic‐associated suspected ADRs                                                                                                        75                                            73                148
  Incident antibiotic‐associated suspected ADRs during hospital stay                                                                          51                                            66                117
  Serious incident in‐hospital suspected ADRs                                                                                                 23                                            16                39
  Prevalent antibiotic‐associated suspected ADRs at admission                                                                                 38                                            7                 45
  Serious prevalent suspected ADRs at admission                                                                                               23                                            1                 24
  Community‐acquired antibiotic‐associated suspected ADRs                                                                                     47                                            17                64
  Incident community‐acquired suspected ADRs during hospital stay                                                                             18                                            9                 27
  Serious incident community‐acquired suspected ADRs                                                                                          7                                             2                 9
  Hospital‐acquired antibiotic‐assoc. suspected ADRs                                                                                          33                                            61                94
  Serious incident hospital‐acquired suspected ADRs                                                                                           16                                            16                32
                                                                                                                                              Proportion with suspected ADRs, % (*n*/*N*)                     
  Characteristic at patient‐level                                                                                                             HIV+                                          HIV‐ or Unknown   Total
  Overall, suspected ADRs[b](#prp2298-note-0005){ref-type="fn"}                                                                               59% (136/232)                                 35% (184/530)     42% (320/762)
  Antibiotic‐associated community‐ or hospital‐acquired suspected ADRs                                                                                                                                        
  Percent of overall sample[b](#prp2298-note-0005){ref-type="fn"}                                                                             32% (75/232)                                  14% (73/530)      19% (148/762)
  Percent of patients who experienced at least one ADR[b](#prp2298-note-0005){ref-type="fn"}                                                  55% (75/136)                                  40% (73/184)      46% (148/320)
  Prevalence of antibiotic‐associated community‐acquired ADRs                                                                                                                                                 
  At hospital admission[b](#prp2298-note-0005){ref-type="fn"}                                                                                 16% (38/232)                                  1% (7/530)        6% (45/762)
  Among antibiotic‐users in the 4‐weeks preadmission[b](#prp2298-note-0005){ref-type="fn"}                                                    21% (38/178)                                  6% (7/122)        15% (45/300)
  Prevalence of serious community‐acquired ADRs[b](#prp2298-note-0005){ref-type="fn"}                                                         13% (23/178)                                  1% (1/122)        8% (24/300)
  Incidence of antibiotic‐associated suspected ADRs                                                                                                                                                           
  Incidence (overall) of community‐ or hospital‐acquired ADRs[a](#prp2298-note-0004){ref-type="fn"}, [b](#prp2298-note-0005){ref-type="fn"}   22% (51/228)                                  16% (66/401)      19% (117/629)
  Incidence of community‐acquired ADRs during hospital stay                                                                                   10% (18/178)                                  7% (9/122)        9% (27/300)
  Incidence of hospital‐acquired ADRs during hospital stay                                                                                    15% (33/221)                                  16% (61/382)      16% (94/603)
  Incidence (overall) of serious community/hospital‐acquired ADRs[b](#prp2298-note-0005){ref-type="fn"}                                       10% (23/228)                                  4% (16/401)       6% (39/629)
  Incidence of serious community‐acquired ADRs                                                                                                4% (7/178)                                    2% (2/122)        3% (9/300)
  Incidence of serious hospital‐acquired ADRs                                                                                                 7% (16/221)                                   4% (16/382)       5% (32/603)

Some patients experienced more than one community‐acquired or hospital‐acquired antibiotic‐associated suspected ADR with incidence overlap in four patients.

Statistically significant difference at *P* \< 0.05.

John Wiley & Sons, Ltd

Prevalence of community‐acquired aa‐ADRs {#prp2298-sec-0012}
----------------------------------------

The prevalence of community‐acquired aa‐ADRs was 6% (45/762; 95% CI: 4--8%) of all patients or 15% (45/300; 95% CI: 11--20%) of those who had received antibiotics in the 4‐weeks preadmission. Serious prevalent aa‐ADRs were encountered by 8% (24/300; 95% CI: 5--12%) of patients who used antibiotics preadmission or by half (53%, 24/45; 95% CI: 39--68%) of those with prevalent aa‐ADRs, see Table [2](#prp2298-tbl-0002){ref-type="table-wrap"}.

The prevalence of aa‐ADRs among preadmission antibiotic‐users was three‐fold higher among HIV‐positive vs. HIV‐negative/unknown serostatus inpatients \[21% (38/178) vs. 6% (7/122); *χ* ^2^ = 13.8; *P* \< 0.001\]; and 13‐fold higher for serious prevalent aa‐ADRs \[13% (23/178) vs. 1% (1/122); *χ* ^2^ = 14.4; *P* \< 0.001\], see Table [2](#prp2298-tbl-0002){ref-type="table-wrap"}.

Incidence of aa‐ADRs during hospitalization {#prp2298-sec-0013}
-------------------------------------------

The incidence of aa‐ADRs was 19% (117/629; 95% CI: 16--22%) of inpatients who received antibiotics \[community‐acquired: 9% (27/300; 95% CI: 6--13%); hospital‐acquired: 16% (94/603; 95% CI: 13--19%)\], four patients having developed incident community‐acquired and hospital‐acquired aa‐ADRs during the current hospitalization, see Tables [1](#prp2298-tbl-0001){ref-type="table-wrap"}, [2](#prp2298-tbl-0002){ref-type="table-wrap"}. Serious incident aa‐ADRs were encountered by 6% (39/629; 95% CI: 4--8%) of patients or by one‐third (33%, 39/117; 95% CI: 25--42%) of those with incident aa‐ADRs, see Table [2](#prp2298-tbl-0002){ref-type="table-wrap"}.

The incidence of serious community‐acquired/hospital‐acquired aa‐ADRs was two‐fold higher among HIV‐positive vs. HIV‐negative/unknown serostatus inpatients \[10% (23/228) vs. 4% (16/401); *χ* ^2^ = 9.3; *P* = 0.002\].

Suspected aa‐ADRs by single antibiotic class, individual antibiotic, and system organ class {#prp2298-sec-0014}
-------------------------------------------------------------------------------------------

At the suspected ADR level of analysis, antibiotics contributed 41% (269/662) of all suspected ADRs (148 patients shared 269 aa‐ADRs), 44% (118/269) of which were linked to a single antibiotic class only. Ceftriaxone accounted for 43% (50/117) of aa‐ADRs attributable to individual antibiotics only, followed by metronidazole (21%, 24/117) and cotrimoxazole (13%, 15/117). Forty‐three percent (115/269) of aa‐ADRs were community‐acquired. Hospital‐acquired aa‐ADRs were more likely than community‐acquired aa‐ADRs to involve a single antibiotic class only (56% vs. 27%), see Table [3](#prp2298-tbl-0003){ref-type="table-wrap"}.

###### 

Distribution of 269 antibiotic‐associated suspected ADRs at ADR‐level, Uganda, 2014

  Characteristic at suspected ADR‐level[a](#prp2298-note-0006){ref-type="fn"}                                 HIV status, % (*n*/*N*)                   
  ----------------------------------------------------------------------------------------------------------- ------------------------- --------------- ---------------
  Proportion of suspected ADRs that are antibiotic‐associated                                                 43% (131/302)             38% (138/360)   41% (269/662)
  Number of antibiotic classes                                                                                                                          
  One antibiotic class only[c](#prp2298-note-0008){ref-type="fn"}                                             34% (44/131)              54% (74/138)    44% (118/269)
  Two or more antibiotic classes only[c](#prp2298-note-0008){ref-type="fn"}                                   10% (13/131)              19% (26/138)    15% (39/269)
  One or more antibiotic class(es) + one or more other drug class(es)[c](#prp2298-note-0008){ref-type="fn"}   56% (74/131)              28% (38/138)    42% (112/269)
  Individual antibiotics only [b](#prp2298-note-0007){ref-type="fn"}                                                                                    
  Ceftriaxone (J01DD04)                                                                                       35% (17/49)               49% (33/68)     43% (50/117)
  Metronidazole (J01XD01) & (P01AB01)                                                                         12% (6/49)                26% (18/68)     21% (24/117)
  Cotrimoxazole (J01EE01)[c](#prp2298-note-0008){ref-type="fn"}                                               31% (15/49)               0% (0/68)       13% (15/117)
  Isoniazid[c](#prp2298-note-0008){ref-type="fn"}                                                             12% (6/49)                0% (0/68)       5% (6/117)
  Ciprofloxacin (J01MA02)                                                                                     2% (1/49)                 7% (5/68)       5% (6/117)
  Erythromycin (J01FA01)                                                                                      2% (1/49)                 6% (4/68)       4% (5/117)
  Azithromycin (J01FA10)                                                                                      0% (0/49)                 7% (5/68)       4% (5/117)
  Levofloxacin (J01MA12)                                                                                      0% (0/49)                 3% (2/68)       2% (2/117)
  Ampicillin‐cloxacillin (J01CR50), Amoxicillin‐clavulanate (J01CR02)                                         2% (1/49)                 1% (1/68)       2% (2/117)
  Rifampicin                                                                                                  4% (2/49)                 0% (0/68)       2% (2/117)
  Community‐acquired or hospital‐acquired aa‐ADRs                                                                                                       
  Proportion of community‐acquired aa‐ADRs[c](#prp2298-note-0008){ref-type="fn"}                              65% (85/131)              22% (30/138)    43% (115/269)
  One antibiotic class only                                                                                   27% (23/85)               27% (8/30)      27% (31/115)
  Two or more antibiotic classes only[c](#prp2298-note-0008){ref-type="fn"}                                   11% (9/85)                50% (15/30)     21% (24/115)
  One or more antibiotic class(es) + one or more other drug class(es)[c](#prp2298-note-0008){ref-type="fn"}   62% (53/85)               23% (7/30)      52% (60/115)
  Proportion of hospital‐acquired aa‐ADRs[c](#prp2298-note-0008){ref-type="fn"}                               35% (46/131)              78% (108/138)   57% (154/269)
  One antibiotic class only                                                                                   46% (21/46)               61% (66/108)    56% (87/154)
  Two or more antibiotic classes only                                                                         9% (4/46)                 10% (11/108)    10% (15/154)
  One or more antibiotic class(es) + one or more other drug class(es)[c](#prp2298-note-0008){ref-type="fn"}   46% (21/46)               29% (31/108)    36% (52/154)

Some patients experienced more than one community‐acquired or hospital‐acquired antibiotic‐associated suspected ADRs.

One antibiotic‐associated suspected ADR attributed to two antibiotics from the same antibiotic class (quinolones: ciprofloxacin and levofloxacin) was excluded.

Statistically significant difference at *P* \< 0.05.

John Wiley & Sons, Ltd

Individual antibiotics with the highest frequencies of community‐acquired/hospital‐acquired aa‐ADRs were ceftriaxone (110), cotrimozaxole (58), metronidazole (54), isoniazid (35), rifampicin (26), pyrazinamide (23), ethambutol (23), levofloxacin (15), and ciprofloxacin (13), among others. Most cotrimoxazole aa‐ADRs were community‐acquired (54/58), see Table [4](#prp2298-tbl-0004){ref-type="table-wrap"}.

###### 

Individual antibiotics most frequently implicated in causing the 269 antibiotic‐associated suspected ADRs (aa‐ADRs) among 148 of 762 hospitalized patients, Uganda, 2014

  Antibiotic class, antibiotic                       No. of aa‐ADRs[a](#prp2298-note-0009){ref-type="fn"}   No. of community‐acquired aa‐ADRs   No. of hospital‐acquired aa‐ADRs   DDDs used during current hospitalization   No. of Patients who used drug in hospital   No. of hospital‐acquired aa‐ADRs/100 DDDs   95% CIs[b](#prp2298-note-0010){ref-type="fn"} of hospital‐acquired ADRs/100 DDDs
  -------------------------------------------------- ------------------------------------------------------ ----------------------------------- ---------------------------------- ------------------------------------------ ------------------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------
  Cephalosporins                                                                                                                                                                                                                                                                                                      
  Ceftriaxone                                        110                                                    16                                  94                                 398.0                                      398                                         24                                          19--28
  Penicillins                                                                                                                                                                                                                                                                                                         
  Ampicillin[c](#prp2298-note-0011){ref-type="fn"}   2                                                      0                                   2                                  8.8                                        11                                          23                                          0--50
  Amoxicillin‐clavulanate                            1                                                      0                                   1                                  19.0                                       8                                           5                                           0--15
  Amoxicillin                                        6                                                      4                                   2                                  169.0                                      57                                          1                                           0--6
  Ampicillin‐cloxacillin                             1                                                      1                                   0                                  24.4                                       32                                          0                                           0--4
  Quinolones                                                                                                                                                                                                                                                                                                          
  Levofloxacin                                       15                                                     0                                   15                                 62.0                                       17                                          24                                          14--35
  Ciprofloxacin                                      13                                                     3                                   10                                 279.9                                      114                                         4                                           1--6
  Nitroimidazole derivatives                                                                                                                                                                                                                                                                                          
  Metronidazole                                      54                                                     10                                  44                                 309.1                                      246                                         14                                          10--18
  Sulfonamides and trimethoprim                                                                                                                                                                                                                                                                                       
  Cotrimoxazole                                      58                                                     54                                  4                                  358.0                                      162                                         1                                           0--6
  Macrolide antibiotics                                                                                                                                                                                                                                                                                               
  Erythromycin                                       12                                                     6                                   6                                  79.5                                       19                                          8                                           2--13
  Azithromycin                                       8                                                      2                                   6                                  123.3                                      26                                          5                                           1--9
  Aminoglycosides                                                                                                                                                                                                                                                                                                     
  Gentamicin                                         1                                                      0                                   1                                  15.0                                       12                                          7                                           0--19
  Antileprotics                                                                                                                                                                                                                                                                                                       
  Dapsone                                            3                                                      3                                   0                                  0.0                                        5                                           0                                           0--4
  Antituberculous drugs                                                                                                                                                                                                                                                                                               
  Pyrazinamide                                       23                                                     21                                  2                                  117.3                                      38                                          2                                           0--7
  Isoniazid                                          35                                                     33                                  2                                  155.8                                      49                                          1                                           0--6
  Rifampicin                                         26                                                     25                                  1                                  113.8                                      40                                          1                                           0--6
  Ethambutol                                         23                                                     22                                  1                                  122.8                                      46                                          1                                           0--6

One or more antibiotics or other drug class(es) may have been implicated in the causation of an aa‐ADR.

CIs is confidence intervals.

95% CIs are wide and include null value.

John Wiley & Sons, Ltd

The highest incidence‐rates of hospital‐acquired aa‐ADRs, standardized by DDDs, were from ceftriaxone (24 aa‐ADRs/100 DDDs), levofloxacin (24 aa‐ADRs/100 DDDs), and metronidazole (14 aa‐ADRs/100 DDDs); though levofloxacin consumption was quite low (*n* = 17; DDDs = 62), see Table [4](#prp2298-tbl-0004){ref-type="table-wrap"}. Ceftriaxone showed stronger signals for hospital‐acquired aa‐ADRs than metronidazole in both HIV‐positive \[(19 per 100 DDDs) vs. (10 per 100 DDDs); *P* = 0.046\] and HIV‐negative/unknown status \[(26 per 100 DDDs) vs. (17 per 100 DDDs); *P* = 0.014\] patients, respectively, see Table [S1](#prp2298-sup-0002){ref-type="supplementary-material"}.

The incidence of serious hospital‐acquired aa‐ADRs, standardized by DDDs, was highest for ceftriaxone (7 aa‐ADRs/100 DDDs) followed by metronidazole (3 aa‐ADRs/100 DDDs) and levofloxacin (2 aa‐ADRs/100 DDDs).

The system organ classes most frequently affected were the gastrointestinal (50%, 135/269), neurological (24%, 64/269), body‐general (10%, 27/269), and skin/appendages (6%, 17/269), among others. Serious aa‐ADRs from patients of known HIV‐positive status were significantly more frequent in the gastrointestinal \[HIV‐positive: 35% (20/57) vs. HIV‐negative/unknown: 6% (5/78); *χ* ^2^ = 17.9; *P* \< 0.001\] and neurological \[HIV‐positive: 52% (15/29) vs. HIV‐negative/unknown: 20% (7/35); *χ* ^2^ = 7.1; *P* = 0.008\] systems, see Table [5](#prp2298-tbl-0005){ref-type="table-wrap"}.

###### 

System Organ Class distribution of the 269 antibiotic‐associated suspected ADRs experienced by 148 hospitalized patients, Uganda, 2014

  System Organ Class (SOC) name                                      No. of aa‐ADRs (% column)   No. of serious aa‐ADRs (% row)   Serious aa‐ADRs by HIV‐status, % (*n*/*N*)   
  ------------------------------------------------------------------ --------------------------- -------------------------------- -------------------------------------------- ------------
  Gastrointestinal disorders[a](#prp2298-note-0012){ref-type="fn"}   135 \[50\]                  25 (19)                          35% (20/57)                                  6% (5/78)
  Neurological disorders[a](#prp2298-note-0012){ref-type="fn"}       64 \[24\]                   22 (34)                          52% (15/29)                                  20% (7/35)
  Body -- General disorders                                          27 \[10\]                   13 (48)                          60% (9/15)                                   33% (4/12)
  Skin and appendages disorders                                      17 \[6\]                    5 (29)                           33% (4/12)                                   20% (1/5)
  Others                                                             26 \[10\]                   21 (81)                          83% (15/18)                                  75% (6/8)

Statistically significant difference in proportions of serious ADRs by HIV‐status at *P* \< 0.05 (gastrointestinal: *χ* ^2^ = 17.9; *P* \< 0.001 & neurological: *χ* ^2^ = 7.1; *P* = 0.008).
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Causality, preventability and severity of aa‐ADRs {#prp2298-sec-0015}
-------------------------------------------------

Only 25% (66/269) of aa‐ADRs were of probable/definite causality. Vomiting was the commonest aa‐ADR in both the possible (17%, 35/203) and probable/definite (20%, 13/66) causality categories. Loss of appetite (12%, 25/203) was the only aa‐ADR in the top 10 most frequent possible aa‐ADRs that did not feature among the top 10 most frequent probable/definite aa‐ADRs, see Table [S2](#prp2298-sup-0003){ref-type="supplementary-material"}.

Most aa‐ADRs were preventable (64%, 171/269). However, 65% (43/66) of probable/definite aa‐ADRs were nonpreventable. Table** ** [6](#prp2298-tbl-0006){ref-type="table-wrap"} shows that one in seven (14%, 38/269) aa‐ADRs was severe (grade three intensity).

###### 

Severity, seriousness, and rarity of 269 antibiotic‐associated suspected ADRs in hospitalized patients, Uganda, 2014

  Assessment                                                                      Category                                    Frequency of suspected aa‐ADRs (*n*, %)[a](#prp2298-note-0013){ref-type="fn"}
  ------------------------------------------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------------
  Severity[a](#prp2298-note-0013){ref-type="fn"}                                  Mild                                        110 (41)
  Moderate                                                                        120 (45)                                    
  Severe                                                                          38 (14)                                     
  Life‐threatening                                                                1 (0)                                       
  Serious                                                                         Yes[a](#prp2298-note-0013){ref-type="fn"}   86 (32)
  Required intervention to prevent damage[b](#prp2298-note-0014){ref-type="fn"}   48 (56)                                     
  Caused or prolonged hospitalization[b](#prp2298-note-0014){ref-type="fn"}       25 (29)                                     
  Other medically significant condition[b](#prp2298-note-0014){ref-type="fn"}     10 (12)                                     
  Caused death[b](#prp2298-note-0014){ref-type="fn"}                              1 (1)                                       
  Life‐threatening[b](#prp2298-note-0014){ref-type="fn"}                          1 (1)                                       
  Caused disability[b](#prp2298-note-0014){ref-type="fn"}                         1 (1)                                       
  No[a](#prp2298-note-0013){ref-type="fn"}                                        183 (68)                                    
  Rare[a](#prp2298-note-0013){ref-type="fn"}                                      Yes                                         24 (9)
  No                                                                              242 (90)                                    
  Incidence unknown                                                               3 (1)                                       

Denominator used was the total number of antibiotic‐associated suspected ADRs, *n* = 269.

Denominator used was the number of serious antibiotic‐associated suspected ADRs, *n* = 86.
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Seriousness of aa‐ADRs {#prp2298-sec-0016}
----------------------

Thirty‐two percent (86/269) of aa‐ADRs were judged as serious: the majority (56%, 48/86) required intervention to prevent permanent damage, and 29% (25/86) caused or prolonged hospitalization. Fatal jaundice \[isoniazid\], disabling itchy skin rash with numbness of lower swollen legs \[ethambutol, isoniazid\] and life‐threatening difficulty in breathing with shortness of breath \[rifampicin\] occurred in known HIV‐positive patients; see Table [7](#prp2298-tbl-0007){ref-type="table-wrap"}.

###### 

List of 86 serious antibiotic‐associated suspected adverse drug reactions experienced by hospitalized patients, Uganda, 2014

  Adverse Drug Reaction                            Drug                                            Severity           Causality   Rarity   HIV‐status   Community or Hospital‐acquired   System Organ Class    Grade of Seriousness
  ------------------------------------------------ ----------------------------------------------- ------------------ ----------- -------- ------------ -------------------------------- --------------------- -----------------------------------------
  FEVER                                            INH, RIFAMPICIN, PYRAZINAMIDE                   Moderate           Possible    No       Negative     Community‐acquired               Body ‐ General        Required intervention to prevent damage
  ANEMIA                                           UNKNOWN HERBAL, CEFTRIAXONE, CAPTOPRIL          Moderate           Possible    No       Negative     Community‐acquired               Blood                 Required intervention to prevent damage
  FEVER                                            CEFTRIAXONE                                     Severe             Possible    No       Negative     Hospital‐acquired                Body ‐ General        Required intervention to prevent damage
  DIZZINESS                                        CEFTRIAXONE                                     Severe             Possible    No       Negative     Hospital‐acquired                Neurological          Required intervention to prevent damage
  VOMITING                                         CEFTRIAXONE, TRAMADOL                           Severe             Possible    No       Negative     Hospital‐acquired                Gastrointestinal      Required intervention to prevent damage
  FEVER                                            CEFTRIAXONE                                     Severe             Possible    No       Negative     Hospital‐acquired                Body ‐ General        Required intervention to prevent damage
  DIZZINESS                                        CEFTRIAXONE, METRONIDAZOLE                      Moderate           Possible    No       Negative     Hospital‐acquired                Neurological          Required intervention to prevent damage
  PERIPHERAL NEUROPATHY                            LEVOFLOXACIN                                    Moderate           Possible    No       Negative     Hospital‐acquired                Neurological          Caused or prolonged Hosp
  TACHYCARDIA                                      CIPROFLOXACIN                                   Moderate           Possible    No       Negative     Hospital‐acquired                Cardiovascular        Required intervention to prevent damage
  DIZZINESS                                        METRONIDAZOLE, AMOXICILLIN                      Severe             Possible    NK       Negative     Hospital‐acquired                Neurological          Caused or prolonged Hosp
  WORSENED JAUNDICE                                CIPROFLOXACIN, CEFTRIAXONE, METRONIDAZOLE       Moderate           Possible    No       Negative     Hospital‐acquired                Liver and biliary     Other medically significant condition
  CONVULSIONS ‐ GTC (2 EPISODES)                   METRONIDAZOLE                                   Severe             Possible    No       Negative     Hospital‐acquired                Neurological          Required intervention to prevent damage
  VOMITING                                         CEFTRIAXONE                                     Severe             Possible    No       Negative     Hospital‐acquired                Gastrointestinal      Other medically significant condition
  ORAL SORES                                       CEFTRIAXONE                                     Moderate           Possible    No       Negative     Hospital‐acquired                Gastrointestinal      Other medically significant condition
  HYPERTENSION                                     CIPROFLOXACIN                                   Severe             Probable    No       Negative     Hospital‐acquired                Cardiovascular        Required intervention to prevent damage
  PARESTHESIA                                      CEFTRIAXONE                                     Moderate           Probable    NK       Negative     Hospital‐acquired                Neurological          Other medically significant condition
  ITCHING SKIN ‐ MULTIFORME RASH                   DICLOFENAC, METRONIDAZOLE                       Moderate           Probable    No       Negative     Hospital‐acquired                Skin and appendages   Required intervention to prevent damage
  PARESTHESIAS (PERIPHERAL NEUROPATHY)             HRZE                                            Severe             Possible    No       Unknown      Community‐acquired               Neurological          Required intervention to prevent damage
  HIGH GRADE FEVER WITH CHILLS AND RIGOR           HRZE                                            Severe             Possible    No       Unknown      Community‐acquired               Body ‐ General        Caused or prolonged Hosp
  BLURRED VISION                                   METRONIDAZOLE                                   Mild               Possible    No       Unknown      Hospital‐acquired                Vision                Other medically significant condition
  VOMITING (3 EPISODES)                            CEFTRIAXONE, TRAMADOL                           Mild               Possible    No       Unknown      Hospital‐acquired                Gastrointestinal      Other medically significant condition
  LOSS OF APPETITE                                 METRONIDAZOLE                                   Moderate           Possible    No       Unknown      Hospital‐acquired                Gastrointestinal      Caused or prolonged Hosp
  DECREASED URINE OUTPUT                           CEFTRIAXONE                                     Severe             Probable    Yes      Unknown      Hospital‐acquired                Urinary tract         Other medically significant condition
  LOSS OF APPETITE                                 CTX, METRONIDAZOLE                              Moderate           Possible    No       Positive     Community‐acquired               Gastrointestinal      Required intervention to prevent damage
  PARESTHESIAS                                     3TC, CTX                                        Moderate           Possible    No       Positive     Community‐acquired               Neurological          Other medically significant condition
  FEVER                                            AZT/3TC/EFV, CTX                                Severe             Possible    No       Positive     Community‐acquired               Body ‐ General        Required intervention to prevent damage
  SEVERE PALLOR OF MUCUS MEMBRANES                 HRZE, TDF/3TC/NVP, CTX                          Severe             Possible    No       Positive     Community‐acquired               Blood                 Required intervention to prevent damage
  DIZZINESS                                        HRZE, TDF/3TC, CTX                              Severe             Possible    No       Positive     Community‐acquired               Neurological          Caused or prolonged Hosp
  PRODUCTIVE COUGH                                 CTX, TDF/3TC                                    Severe             Possible    No       Positive     Community‐acquired               Respiratory           Required intervention to prevent damage
  JAUNDICE                                         HRZE, TDF/3TC, CTX                              Moderate           Possible    No       Positive     Community‐acquired               Liver and biliary     Required intervention to prevent damage
  DIFFICULTY IN BREATHING                          RIFAMPICIN, TDF/3TC, CTX                        Severe             Possible    No       Positive     Community‐acquired               Respiratory           Required intervention to prevent damage
  NUMBNESS OF BOTH LOWER LIMBS                     HE, 3TC, CTX                                    Moderate           Possible    No       Positive     Community‐acquired               Neurological          Required intervention to prevent damage
  DIZZINESS                                        COARTEM, DAPSONE, FLUCONAZOLE                   Moderate           Possible    No       Positive     Community‐acquired               Neurological          Required intervention to prevent damage
  PARAPARESIS                                      INH                                             Moderate           Possible    No       Positive     Community‐acquired               Neurological          Caused or prolonged Hosp
  JAUNDICE                                         INH                                             Life‐threatening   Possible    No       Positive     Community‐acquired               Liver and biliary     Caused death
  GENERALIZED MACULO‐PAPULAR RASH                  CTX, ARVS (TDF/3TC/EFV)                         Moderate           Possible    No       Positive     Community‐acquired               Skin and appendages   Caused or prolonged Hosp
  VOMITING                                         FLUCONAZOLE, ACICLOVIR, CEFTRIAXONE             Moderate           Possible    Yes      Positive     Community‐acquired               Gastrointestinal      Caused or prolonged Hosp
  SEVERE ANEMIA 3.4G/DL                            TDF/3TC, CTX                                    Severe             Possible    No       Positive     Community‐acquired               Blood                 Caused or prolonged Hosp
  WORSENED PALLOR                                  TDF/3TC, CTX                                    Severe             Possible    No       Positive     Community‐acquired               Skin and appendages   Required intervention to prevent damage
  DIARRHEA                                         TDF/3TC/EFV, CTX                                Moderate           Possible    No       Positive     Community‐acquired               Gastrointestinal      Caused or prolonged Hosp
  HEADACHE                                         CTX                                             Moderate           Possible    No       Positive     Community‐acquired               Neurological          Caused or prolonged Hosp
  VOMITING                                         HRZE                                            Severe             Possible    No       Positive     Community‐acquired               Gastrointestinal      Caused or prolonged Hosp
  ANEMIA                                           CTX                                             Moderate           Possible    No       Positive     Community‐acquired               Blood                 Caused or prolonged Hosp
  ABDOMINAL DISCOMFORT/DISTENTION                  HRZE, AZT                                       Moderate           Possible    No       Positive     Community‐acquired               Gastrointestinal      Other medically significant condition
  PARESTHESIAS                                     CTX, TDF/3TC/LPV/RTV                            Moderate           Possible    No       Positive     Community‐acquired               Neurological          Required intervention to prevent damage
  PERSISTENT DIARRHOEA                             3TC/TDF/EFV, CTX                                Severe             Possible    No       Positive     Community‐acquired               Gastrointestinal      Caused or prolonged Hosp
  VOMITING                                         3TC/TDF/EFV, CTX                                Severe             Possible    No       Positive     Community‐acquired               Gastrointestinal      Required intervention to prevent damage
  ANOREXIA                                         3TC/TDF, CTX                                    Moderate           Possible    No       Positive     Community‐acquired               Gastrointestinal      Required intervention to prevent damage
  JOINT PAIN                                       3TC/TDF, CTX                                    Severe             Possible    No       Positive     Community‐acquired               Musculoskeletal       Required intervention to prevent damage
  DEEP JAUNDICE                                    RHZ, AZT/3TC                                    Severe             Possible    No       Positive     Community‐acquired               Liver and biliary     Required intervention to prevent damage
  PERIPHERAL NEUROPATHY                            AZT, 3TC, INH                                   Moderate           Possible    No       Positive     Community‐acquired               Neurological          Other medically significant condition
  COUGH                                            TDF/3TC, CTX                                    Severe             Possible    No       Positive     Community‐acquired               Respiratory           Required intervention to prevent damage
  DRY COUGH WITH SHORTNESS OF BREATH               CTX                                             Severe             Possible    Yes      Positive     Community‐acquired               Respiratory           Required intervention to prevent damage
  DIZZINESS                                        METRONIDAZOLE                                   Severe             Possible    No       Positive     Community‐acquired               Neurological          Required intervention to prevent damage
  DIZZINESS                                        TDF/3TC, RHZE                                   Moderate           Probable    No       Positive     Community‐acquired               Neurological          Required intervention to prevent damage
  LOSS OF APPETITE                                 3TC, TDF, RIFAMPICIN, PYRAZINAMIDE              Moderate           Probable    No       Positive     Community‐acquired               Gastrointestinal      Required intervention to prevent damage
  VOMITING                                         HRZE                                            Moderate           Probable    No       Positive     Community‐acquired               Gastrointestinal      Required intervention to prevent damage
  GENERALIZED BODY WEAKNESS                        TDF/3TC, RIFAMPICIN                             Moderate           Probable    No       Positive     Community‐acquired               Body ‐ General        Caused or prolonged Hosp
  HEADACHE                                         INH, RIFAMPICIN                                 Moderate           Probable    No       Positive     Community‐acquired               Neurological          Required intervention to prevent damage
  CONSTIPATION                                     INH                                             Moderate           Probable    No       Positive     Community‐acquired               Gastrointestinal      Required intervention to prevent damage
  PRURITUS                                         TDF/EFV, METRONIDAZOLE, INH, ETHAMBUTOL         Severe             Probable    No       Positive     Community‐acquired               Skin and appendages   Caused or prolonged Hosp
  ITCHY RASH WITH NUMBNESS OF LOWER SWOLLEN LEGS   HE, CARVEDILOL                                  Moderate           Probable    No       Positive     Community‐acquired               Skin and appendages   Caused disability
  JAUNDICE                                         CTX                                             Moderate           Probable    No       Positive     Community‐acquired               Liver and biliary     Required intervention to prevent damage
  PERIPHERAL NEUROPATHY                            3TC, METRONIDAZOLE                              Moderate           Probable    Yes      Positive     Community‐acquired               Neurological          Caused or prolonged Hosp
  DIB WITH SHORTNES OF BREATH                      RIFAMPCIN                                       Severe             Probable    No       Positive     Community‐acquired               Respiratory           Life‐threatening
  ANEMIA                                           CTX, TDF/3TC/LPV/RTV                            Moderate           Probable    No       Positive     Community‐acquired               Blood                 Caused or prolonged Hosp
  PEDAL EDEMA                                      RIFAMPICIN                                      Severe             Probable    No       Positive     Community‐acquired               Cardiovascular        Required intervention to prevent damage
  PARESTHESIA                                      HRZE                                            Mild               Probable    No       Positive     Community‐acquired               Neurological          Caused or prolonged Hosp
  VOMITING                                         CEFTRIAXONE, METRONIDAZOLE, BLOOD, DICLOFENAC   Severe             Possible    No       Positive     Hospital‐acquired                Gastrointestinal      Required intervention to prevent damage
  DIZZINESS                                        CEFTRIAXONE, METRONIDAZOLE, DICLOFENAC          Moderate           Possible    No       Positive     Hospital‐acquired                Neurological          Required intervention to prevent damage
  FEVER                                            CTX, TDF/3TC/EFV                                Moderate           Possible    No       Positive     Hospital‐acquired                Body ‐ General        Required intervention to prevent damage
  FEVER                                            CEFTRIAXONE                                     Moderate           Possible    No       Positive     Hospital‐acquired                Body ‐ General        Required intervention to prevent damage
  VOMITING                                         CEFTRIAXONE, TDF/3TC/EFV                        Severe             Possible    No       Positive     Hospital‐acquired                Gastrointestinal      Caused or prolonged Hosp
  DIZZINESS                                        CEFTRIAXONE, METOCLOPRAMIDE                     Moderate           Possible    No       Positive     Hospital‐acquired                Neurological          Caused or prolonged Hosp
  VOMITING                                         CEFTRIAXONE                                     Moderate           Possible    No       Positive     Hospital‐acquired                Gastrointestinal      Caused or prolonged Hosp
  FEVER 39.6C                                      CEFTRIAXONE                                     Severe             Possible    No       Positive     Hospital‐acquired                Body ‐ General        Caused or prolonged Hosp
  FEVER 38.3C                                      ACICLOVIR, CEFTRIAXONE                          Severe             Possible    No       Positive     Hospital‐acquired                Body ‐ General        Caused or prolonged Hosp
  ANOREXIA                                         CTX                                             Moderate           Possible    No       Positive     Hospital‐acquired                Gastrointestinal      Required intervention to prevent damage
  DIARRHEA                                         CEFTRIAXONE                                     Moderate           Possible    No       Positive     Hospital‐acquired                Gastrointestinal      Required intervention to prevent damage
  SEVERE ABDOMINAL PAIN                            CIPROFLOXACIN                                   Severe             Possible    No       Positive     Hospital‐acquired                Gastrointestinal      Required intervention to prevent damage
  VOMITING                                         CEFTRIAXONE                                     Severe             Possible    No       Positive     Hospital‐acquired                Gastrointestinal      Caused or prolonged Hosp
  HIGH GRADE FEVER 39.2C                           CEFTRIAXONE                                     Severe             Possible    No       Positive     Hospital‐acquired                Body ‐ General        Required intervention to prevent damage
  VOMITING                                         ERYTHROMYCIN, CEFTRIAXONE                       Severe             Probable    No       Positive     Hospital‐acquired                Gastrointestinal      Required intervention to prevent damage
  FEVER 38.5C                                      CEFTRIAXONE                                     Moderate           Probable    No       Positive     Hospital‐acquired                Body ‐ General        Required intervention to prevent damage
  FEVER 38 C                                       CEFTRIAXONE, DUOVIR‐N, INH, PYRAZINAMIDE        Mild               Probable    No       Positive     Hospital‐acquired                Body ‐ General        Required intervention to prevent damage
  VOMITING                                         CEFTRIAXONE                                     Moderate           Probable    No       Positive     Hospital‐acquired                Gastrointestinal      Required intervention to prevent damage

CTX, Cotrimoxazole; GTC, General Tonic‐Clonic; INH, Isoniazid; HE, Isoniazid/Ethambutol; Hosp, Hospital; RHZ, Rifampicin/Isoniazid/Pyrazinamide; HRZE, Isoniazid/rifampicin/pyrazinamide/ethambutol; AZT, Zidovudine; TDF, Tenofovir; 3TC, lamivudine; NVP, nevirapine; EFV, Efavirenz; LPV, Lopinavir; RTV, Ritonavir; ARVS, Antiretrovirals; DUOVIR‐N, Zidovudine/lamivudine/nevirapine; NK, Incidence unknown; DIB, Difficulty in Breathing.

John Wiley & Sons, Ltd

Seventy‐three percent (63/86) of serious aa‐ADRs were from HIV‐positive patients, mostly community‐acquired (71%, 45/63): with cotrimoxazole (24/45) and antituberculous drugs \[(22/45): isoniazid (17/45), rifampicin (15/45), ethambutol (11/45), and pyrazinamide (10/45)\] being the most frequently implicated. The loss of appetite (4), cough (4), peripheral neuropathy (3), and anemia (3) linked to cotrimoxazole use occurred thrice or more and, similarly, peripheral neuropathy (4) and jaundice (3) for antituberculous drugs.

Ceftriaxone was the most frequently linked to serious hospital‐acquired aa‐ADRs \[70% (26/37); HIV‐positive: 83% (15/18) & HIV‐negative/unknown status: 58% (11/19)\]: the commonest being fever (6) and vomiting (6), see Tables [7](#prp2298-tbl-0007){ref-type="table-wrap"}, [S3](#prp2298-sup-0004){ref-type="supplementary-material"}.

Allergic aa‐ADRs {#prp2298-sec-0017}
----------------

Allergic reactions occurred in 22% (32/148, 95% CI: 15--29%) of patients who experienced aa‐ADRs \[community‐acquired: 19% (12/62; 95% CI: 10--31%); hospital‐acquired: 26% (24/94; 95% CI: 17--36%)\]: 14 (44%) of 32 allergic reactions were serious.

A quarter of the patients who were admitted with at least one ADR related to any medication class had prevalent community‐acquired aa‐ADRs. (15/62; 24%, 95% CI: 14--37%).

Rarity of aa‐ADRs {#prp2298-sec-0018}
-----------------

Nine percent (24/269) of aa‐ADRs, see Tables [7](#prp2298-tbl-0007){ref-type="table-wrap"}, [S4](#prp2298-sup-0005){ref-type="supplementary-material"}, experienced by 22 patients were rare. Twelve rare aa‐ADRs were attributed to metronidazole, those in *italics* being of the *central nervous system* \[*dizziness* (4), constipation (3), *convulsions* (1), *blurred vision* (1), facial itchy skin rash (1), fever (1), and *headache* (1)\]; and six to cotrimoxazole \[anorexia (3), jaundice (1), dry cough with shortness of breath (1), and anemia (1)\]. Nine of the 24 rare aa‐ADRs were serious: four linked to cotrimoxazole (jaundice, anorexia, anemia, and dry cough with shortness of breath), three to metronidazole (*blurred vision, convulsions, and dizziness*), one to levofloxacin (peripheral neuropathy), and one to ceftriaxone (decreased urine output). Moderate jaundice (cotrimoxazole) and severe decreased urine output (ceftriaxone) were nonpreventable rare and serious aa‐ADRs of probable causality, whereas the rest of the rare and serious aa‐ADRs were of possible causality, see Table [S4](#prp2298-sup-0005){ref-type="supplementary-material"}. The jaundice linked to cotrimoxazole occurred in a 33‐year‐old HIV‐positive female who had not yet commenced antiretroviral therapy; the patient\'s other working diagnoses were acute gastroenteritis and dysentery. The severe decreased urine output linked to ceftriaxone occurred in an 18‐year‐old HIV‐positive male not yet on antiretroviral therapy whose other working diagnosis was bronchopneumonia: This patient\'s final diagnosis was acute kidney injury.

Half the rare aa‐ADRs (12/24) were community‐acquired, eight of which were cotrimoxazole‐linked and four metronidazole‐linked. Eight of the 12 hospital‐acquired rare aa‐ADRs were attributed to metronidazole use and three to ceftriaxone, see Table [S4](#prp2298-sup-0005){ref-type="supplementary-material"}.

Discussion {#prp2298-sec-0019}
==========

Suspected aa‐ADRs were common both at admission and during hospital stay. The incidence of aa‐ADRs in our study was threefold higher than that observed in a French cohort of 3963 hospitalized patients (Courjon et al. [2013](#prp2298-bib-0010){ref-type="ref"}) which could, in part, be linked to the higher consumption of antibiotics by our inpatients for HIV‐associated comorbidities. Most of our inpatients received antibiotics whose use was significantly higher among HIV‐infected patients (Kiguba et al. [2016a](#prp2298-bib-0015){ref-type="ref"}). The medical wards showed a higher HIV‐seroprevalence (38%) than gynecology where HIV‐seroprevalence (9%) was similar to the national estimate (7.3%) (Uganda AIDS Commission, [2015](#prp2298-bib-0031){ref-type="ref"}). The fact that most patients received antibiotics makes our study epidemiologically efficient. Few aa‐ADRs would be observed in a hospitalized‐population in which antibiotic prescribing was infrequent. Of all suspected ADRs attributed to any medication class, a large proportion (one in three) was linked to antibiotics, which corroborates findings from South Africa, a setting with a similarly high HIV/AIDS burden, where one in five ADRs (11/51) was antibiotic‐associated (Mehta et al. [2008](#prp2298-bib-0020){ref-type="ref"}).

Ceftriaxone showed the strongest signal for hospital‐acquired aa‐ADRs, even among HIV‐negative/unknown serostatus patients, which could be a reflection of ceftriaxone\'s high prescription rate in our hospital setting. Strong signals were also shown by metronidazole and levofloxacin (based on small numbers of patients for levofloxacin). Unmasking of the signal from the infrequently used levofloxacin demonstrates the utility of standardizing absolute aa‐ADRs by DDDs administered (Hamad et al. [2013](#prp2298-bib-0012){ref-type="ref"}). However, much larger well‐designed epidemiological studies in Uganda and other similar resource‐limited settings could provide more clues on the aa‐ADR profiles of ceftriaxone and levofloxacin, which are otherwise generally known to be safe. We did not test the quality of the antibiotics used and hence how this impacted on the incidence of hospital‐acquired aa‐ADRs by individual antibiotics. Nonetheless, this study has identified individual antibiotics (ceftriaxone, metronidazole, levofloxacin) with potentially higher risk for hospital‐acquired aa‐ADRs. The identified antibiotics can be prioritized for routine pharmaceutical quality assessment in resource‐limited settings where the challenge of counterfeit and substandard drugs prevails (Almuzaini et al. [2013](#prp2298-bib-0005){ref-type="ref"}).

Community‐acquired aa‐ADRs were mostly linked to the preadmission use of cotrimoxazole for prevention of, and antituberculous drugs for treatment of, HIV‐associated opportunistic infections. The cotrimoxazole link to community‐acquired aa‐ADRs is in accordance with previous research in the US (Shehab et al. [2008](#prp2298-bib-0028){ref-type="ref"}) though cotrimoxazole is also a common cause of hospital‐acquired aa‐ADRs in France (Courjon et al. [2013](#prp2298-bib-0010){ref-type="ref"}). Similarly, antituberculous drugs are a major cause of hospital‐acquired aa‐ADRs in South Africa (Mehta et al. [2008](#prp2298-bib-0020){ref-type="ref"}), though most in our study were community‐acquired.

We document a many‐fold higher risk for serious prevalent aa‐ADRs at the time of hospital admission in known HIV‐positive patients. Our study also corroborates findings from the United Kingdom, South Africa, and Rwanda which reported that the incidence of serious community‐acquired‐/hospital‐acquired aa‐ADRs in HIV‐infected patients is at least twice that in HIV‐uninfected patients (Breen et al. [2006](#prp2298-bib-0007){ref-type="ref"}; Marks et al. [2009](#prp2298-bib-0019){ref-type="ref"}; Lorent et al. [2011](#prp2298-bib-0018){ref-type="ref"}), probably due to drug‐drug interactions from concomitant antiretroviral medications (Breen et al. [2006](#prp2298-bib-0007){ref-type="ref"}). Moreover, Marks et al. ([2009](#prp2298-bib-0019){ref-type="ref"}) have argued that the higher incidence of serious aa‐ADRs in South African patients on antituberculous treatment could have been predominated by their HIV‐infection rather than by coadministered antiretroviral therapy.

One in four ADRs related to hospital admission was linked to antibiotic use, which is similar to what is reported in the US (Shehab et al. [2008](#prp2298-bib-0028){ref-type="ref"}), but higher than as observed in Spain (Carrasco‐Garrido et al. [2010](#prp2298-bib-0009){ref-type="ref"}), The Netherlands (van der Hooft et al. [2008](#prp2298-bib-0013){ref-type="ref"}), and India (Sonal et al. [2011](#prp2298-bib-0029){ref-type="ref"}). The fatal, disabling or life‐threatening serious community‐acquired aa‐ADRs linked to individual antituberculous drugs highlight the need for vibrant pharmacovigilance of antituberculous drugs to safeguard patients in our setting where treatment discontinuation or modification may be warranted. The proportion of allergic aa‐ADRs in our cohort (22%), two‐fifths of them serious, was much lower than is reported in the US (79%) (Shehab et al. [2008](#prp2298-bib-0028){ref-type="ref"}), probably by reason of differences in study methodology. Our estimate is based on representatively sampled patients as the unit of analysis, whereas the US study used hospital visits for a drug‐related ADR.

The majority of rare and serious aa‐ADRs were accounted to cotrimoxazole and metronidazole use, yet the number of inpatients who received ceftriaxone during hospital stay was twofold higher than for metronidazole and cotrimoxazole. The aa‐ADRs linked to cotrimoxazole use were probably as a result of long‐term exposure to cotrimoxazole prophylaxis in HIV/AIDS patients. Thus, ongoing close monitoring and documentation of cotrimoxazole\'s safety profile in our setting is critical. Metronidazole and ceftriaxone were mostly initiated during the current admission. The rare aa‐ADRs linked to metronidazole use frequently involved the central nervous system: metronidazole is a small lipophilic molecule that can easily cross the blood--brain barrier and act centrally (Nau et al. [2010](#prp2298-bib-0023){ref-type="ref"}). The high incidence of metronidazole‐associated rare aa‐ADRs during hospital stay should be investigated further. Three percent (8/246; 95% CI: 1.4% to 6.4%) of patients who received metronidazole while in hospital developed a rare hospital‐acquired metronidazole‐associated aa‐ADR. Metronidazole has a BNF list of 22 rare aa‐ADRs (British National Formulary, [2014](#prp2298-bib-0008){ref-type="ref"}). If such aa‐ADRs occur independently within‐patient, the potential rate of occurrence of rare aa‐ADRs among metronidazole users is 22\*1/1000, or 2%. The observed occurence rate of 3% for any rare aa‐ADR is thus consistent with metronidazole being associated with a long list of 22 rare aa‐ADRs.

We suggest that, periodically, Mulago Hospital and possibly other secondary care health facilities in resource‐poor settings could set up ward‐tailored ADR tracking logs, as used in our study, which are formally placed, by default, into patients\' hospital files to log and retrieve, for analysis, ADRs experienced by inpatients. The ADR tracking log has all the data fields of the full suspected ADR reporting form (Form [S1](#prp2298-sup-0001){ref-type="supplementary-material"}) and is efficient for data collection with reduced paper burden. On patient‐discharge, a copy of the log ought to be made for central analysis after every 200--500 such forms have been collected. For health facilities which admit 70--105 patients per week, a 6‐week surveillance period once every 6 months, would suffice. This approach, if well‐coordinated through a local hospital‐based pharmacovigilance unit, will give facility‐specific estimates of antibiotic safety and validate the findings of our study at a much lower cost.

This study had limitations. First, the demanding nature of data collection and high staff costs for high‐quality data limited the number of inpatients studied to the range 600--800 rather than 1200--1500 as initially intended. However, higher than anticipated prevalence at admission and incidence during hospital stay of aa‐ADRs meant that the achieved sample size was sufficient to describe the characteristics of these aa‐ADRs. Second, variations from the planned systematic random sampling approach for recruiting inpatients were minor and unlikely to alter our findings. Third, refusal rates by omitted inpatients were not formally recorded but were low. Fourth, consensus -- rather than individual assessments of aa‐ADR causality and preventability followed by appraisal of interobserver agreement -- was used. Fifth was the challenge of assessing ADR causality in acutely unwell patients with multiple comorbidities and on multiple medications. Hence, we screened patients using an ADR trigger tool to increase the probability to detect aa‐ADRs; and subsequently applied the Naranjo ADR scale to the suspect clinical signs and symptoms to identify those that were at least *possibly* antibiotic‐associated. We held extensive ward‐team discussions and made consultations with the literature before reaching consensus on ADR causality. Sixth, we cannot claim generalizability of our findings to district hospitals, clinics, and other lower level health centers in Uganda. Similar studies conducted in lower level health facilities could elucidate the extent and characteristics of aa‐ADRs in those settings.

Conclusion {#prp2298-sec-0020}
==========

Ceftriaxone showed the highest risk for hospital‐acquired aa‐ADRs (also of serious hospital‐acquired aa‐ADRs), even in HIV‐negative/unknown serostatus patients, probably due to its high consumption. Levofloxacin signaled as high‐risk for hospital‐acquired aa‐ADRs despite its low frequency of in‐hospital use, thus, highlighting the utility of standardizing absolute aa‐ADR counts by DDDs administered. Cotrimoxazole and antituberculous drugs were the most frequently implicated in community‐acquired aa‐ADRs (also in serious community‐acquired aa‐ADRs). Pharmaceutical quality testing of implicated antibiotics in Uganda could be worthwhile. In sentinel settings, periodic on‐ward collection and analysis of antibiotic‐safety‐data standardized by DDDs, such as during a 6‐week surveillance period once every 6 months, should be an efficient method of tracking antibiotics with 1%‐risk for serious aa‐ADRs.
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**Table S2.** Frequencies of individual antibiotic‐associated ADRs in the Probable or Definite vs. Possible ADR causality categories, Uganda, 2014.
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**Table S3.** Serious antibiotic‐associated suspected adverse drug reactions, with preventability, experienced by hospitalized patients, Uganda, 2014.
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**Table S4.** List of 24 rare antibiotic‐associated suspected adverse drug reactions experienced by hospitalized patients, Uganda, 2014.
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